Novo Nordisk CEO's ouster signals stiff competition in the obesity market, getting dominated by Eli Lilly, with Roche, ...

Merck & Co. got a lukewarm “neutral” rating from Citigroup, along with a price target drop from $115 to $84. Other analysts ...

The stock might be down substantially over the past three years, but it isn't out of the picture yet. Teladoc Health is a ...

Bayer and GSK have a Zacks Rank #2 (Buy) each, while Novo Nordisk, AbbVie, and Merck carry a Zacks Rank of 3 (Hold). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

We recently published a list of 13 Best Cheap Stocks to Invest in for Beginners. In this article, we are going to take a look ...

We recently published a list of the 20 Best Dividend Growth Stocks with High Yields. In this article, we are going to take a ...

Shares fell after the company cut its full-year guidance on the back of challenging macroeconomic conditions and ...

Germany's Merck KGaA shares plunged after the company slashed its full-year outlook on the back of uncertainty around tariffs and foreign-exchange headwinds. In European morning trading shares were ...

Merck KGaA, the German science and technology group, trimmed its profit forecast, citing a weakening US dollar and ...

C4 Therapeutics, Inc.’s CCCC share price has dipped by 6.01%, which has investors questioning if this is right time to buy.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Investing.com -- Citi downgraded both AbbVie (NYSE: ABBV) and Merck (NSE: PROR) to Neutral in separate notes Wednesday, ...